HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


White House Eyes Ophthalmologist Roberts For FDA; Frist Is Sponsor

This article was originally published in The Tan Sheet

Executive Summary

White House interest in Cornell ophthalmologist Calvin Roberts, MD, indicates that the search for a permanent FDA commissioner is continuing

You may also be interested in...

FDA Management Hierarchy Under Crawford Takes Shape; Alderson Elevated

The appointment of Center for Veterinary Medicine Office of Research Director Norris Alderson, PhD, as senior associate commissioner for science indicates that acting Commissioner Lester Crawford, PhD, is preparing for a prolonged tenure as head of FDA

FDA Commissioner Search: Wyeth’s Burlington Gets Renewed Consideration

Wyeth exec and former FDA Center for Devices & Radiological Health Director Bruce Burlington, MD, is again under consideration to take over the top position at the agency

PDUFA III Deal Includes Risk Management Fees In “Peri-Approval” Phase

The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts